Immunoassay
Aug 15, 2024
Masimo W1® Medical Watch Secured FDA 510(K) Clearance; Stereotaxis Received the CE Mark in Europe and Submitted a 510(K) Application in the US; Replimune Dosed First Patient in the IGNYTE-3 Clinical Trial; Daré Bioscience Announced the Publication of Positive Findings From the Phase IIb RESPOND Clinical Study; Baxter’s Definitive Agreement to Carlyle For USD 3.8 Billion; Moximed Successfully Closed a USD 91 Million Series D Financing Round
The Masimo W1® Medical Watch Secured FDA 510(K) Clearance for its Connectivity with the Masimo Safetynet® Telemonitoring System On August 12, 2024, Masimo announced that its Masimo W1® medical watch received FDA 510(k) clearance for connectivity. This approval enabled the watch to integrate with the Masimo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
